Ocular Drug Delivery System Market
Market Insights on Ocular Drug Delivery System covering sales outlook, demand forecast & up-to-date key trends
Ocular Drug Delivery System Market by Technology (Implantable Ocular Drug Delivery Systems, Particulate Drug Delivery Systems), Dosage Form (Ophthalmic Solution, Ophthalmic Suspension, Ophthalmic Emulsion), Distribution Channel & Region - Forecast to 2021-2031
Ocular Drug Delivery System Market Snapshot
[250 Pages Report] The Ocular Drug Delivery System Market is forecast to surpass US$ 14.47 Bn in 2021, according to Future Market Insights (FMI). As a result of rising cases of ophthalmic diseases, focus on advanced treatment is rising, enabling surge in ocular drug delivery systems demand at a CAGR of 6.8 % between 2020 and 2031.
As per FMI analysis, global ocular drug delivery systems sales will total US$ 27.82 Bn by 2031. The demand for particulate drug delivery systems will be highest among all. It is expected to account for over 68% of the global market in 2021.
Let us know your requirement to get
100% FREE customization
Key Points Covered in Ocular Drug Delivery System Market Study
- Ocular Drug Delivery System Market estimates and forecast 2016-2031
- Key drivers and restraints impacting market growth
- Segment-wise, Country-wise, and Region-wise Analysis
- Competition Mapping and Benchmarking
- Brand share and Market Share Analysis
- Key Product Innovations and Regulatory Climate
- COVID-19 Impact on Ocular drug delivery system Market and How to Navigate
- Recommendation on Key Winning Strategies
2016-2020 Ocular Drug Delivery System Market Outlook Compared to 2021-2031 Forecast
According to Future Market Insights (FMI), the sales of ocular drug delivery system have grown at an 6.8% CAGR between 2016 and 2020. Ocular drug delivery systems are platforms designed for dispensing drug, biologic, biopharmaceutical, and botanical therapeutics for treating macular degeneration, glaucoma, presbyopia, allergy, anti-viral, dry eye, anti-infective and anti-inflammatory indications.
To overcome ocular drug delivery barriers and improve bioavailability, various conventional and novel drug delivery systems have been developed such as ointments, emulsion, suspensions, aqueous gels, nanomicelles, liposomes, dendrimers, implants, contact lenses, nanoparticles, Nano suspensions, microneedles, and in situ thermosensitive gels for the earlier mention ocular diseases.
The research focus on key market players is on developing tools to improve the efficacy of spatiotemporal drug administration. For instance, in May 2017, pSivida Corp. announced positive 12-month follow-up data of phase 3 trials for its Durasert, a three-year uveitis implant, improving the treatment of posterior uneitis infection.
Research studies on novel drug delivery treatments for posterior eye therapy by using implantable devices and micro- and nanoparticles are expected to increase the efficacy of advanced ocular drug delivery technologies.
Companies specializing in ocular drug delivery technologies are increasing their research and development expenditure constantly. This trend is likely to continue during the forecast period. For instance, in 2016, Valeant Pharmaceuticals International, Inc. invested US$ 421.0 Mn in research and development to develop platforms for ocular drug delivery technologies.
Huge expenditure is required during developmental stages of advanced ocular drug delivery technologies. With the rise in the number of new entrants, the overall research and development expenses are projected to rise exponentially, along with collaborations and licensing agreements with several research institutes.
With pharmaceutical spending consistently rising in developed countries, the demand for ocular drug delivery system is expected to increase.
Emerging markets, especially large markets such as India and China, have significant untapped potential. With rise in disposable income, these nations are continuing to spend on innovative technologies for better treatment modalities.
Future Market Insights projects the global ocular drug delivery system market to rise at 6.8 % CAGR between 2021 and 2031.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystHow are Low Bioavailability of Drugs Affecting the Ocular Drug Delivery System Market?
The low bioavailability of active drug ingredient administered in eye by conventional topical routes such as solutions & ointments is usually a major obstacle to overcome. This is a result of effective multiple physiological barriers for drug entry. The administration of drugs to the posterior segment of the ocular tissue is inhibited by the same factors that account for the poor ocular bioavailability.
To enhance the bioavailability of ocular therapeutics, there are substantial efforts directed towards advanced drug delivery technologies for ophthalmic administration.
Studies exhibit that micellar formulations can improve the bioavailability of the drugs in ocular tissues, suggesting enhanced therapeutic outcomes. Also, derivatizing active pharmaceutical ingredients (API) and enhancing the ocular drug bioavailability using an emulsion as a carrier system is a phenomenal concept followed by key players in this space.
To increase drug penetration through corneal & other ocular barriers in the anterior portion of the eye, key players are focusing on the development of new drug delivery techniques in the ophthalmic market.
What are the Opportunities for Ocular Drug Delivery System Market Growth?
In case of advanced ocular drug delivery systems, insertion techniques are difficult and expulsion of shields occurs, causing the occasional inadvertent loss of the drug. Thus, using penetration enhancers to improve the corneal drug transport.
Use of ocular penetration enhancers like para-cellular pathways and phase transitions systems are likely increase the opportunity for ocular drug delivery system market. Moreover, the protective barrier mechanisms of the human eye arrest the efficiency of drug delivery, providing an opportunity in developing mechanisms to bypass these barriers during drug administration.
Several ongoing clinical trials are executed to understand the efficacy of bypass mechanisms, which is predicted to efficiently address the problem of ocular drug bio-availability.
In June 2016, EyeGate Pharmaceuticals, Inc. announced the interim data of Phase 1b/2a trial of the iontophoretic EGP-437 which demonstrated a safety clinical profile with efficient bypass mechanisms. Such consistent research initiatives undertaken by leading players will bode well for the market.
A unified Market Research Subscription Platform, built for today's disparate research needs.
What are the Factors Restraining Ocular Drug Delivery System Demand?
Ocular inserts and implants provide advantages such as high corneal penetration, greater dissolution area, and sustained release of medication.
However, the foreign body sensation in the eye due to the solidity of the implants lead to discomfort accompanied by irritation, drug dilution, and excessive lachrymation.
Moreover, nasolacrimal drainage through lacrimal canaliculi refers to the systemic absorption of the drug across the gastrointestinal tract or the nasal mucosa, which leads to loss in its overall volume. This reduction in the volume of drug and rare cases of allergic reactions in the lacrimal system after the drug passage are some of the factors restraining the efficiency of ocular drug delivery.
Additionally, the reduction in patient compliance as well as adherence to novel ocular therapies due to high cost and associated complexities are anticipated to act as barriers for advanced drug delivery technologies in the global ocular drug delivery technologies market.
What Is the Impact of the COVID-19 Crisis on Ocular drug delivery system Market?
COVID-19 pandemic is expected to hamper growth prospects for the ocular drug delivery system market. Significant reduction in the physicians’ office visits and subsequent decline in number of prescription and OTC eye drop purchase is expected to hamper the market growth during COVID-19.
However, nationwide COVID-19 vaccine availability and speedy vaccination programs are expected to help the market set on path of recovery in the coming 1-2 years
New eye treatment product launches, branded as well as generic, are expected to hamper growth for a short-term. Besides this, disruption in the supply chain, delay in pipeline research and development, and changing priority of leading healthcare companies will pose challenges for the market.
Ocular Drug Delivery System Market - Country-wise Insights
How Lucrative is the Opportunity in the U.S?
The U.S. holds over 86% share in the ocular drug delivery system market in North America. In the U.S., growth is led by research collaboration and license agreement for clinical products. Rising technological advancements gives opportunity to manufacturers to deliver therapeutic drugs to targeted ocular tissues in sustained form, and provides protection from inflammatory conditions.
Moreover, expansion strategies are implemented by some of the leading manufacturers in the country to strengthen their product portfolio. For instance, in October, 2020, Ocular Therapeutix™ and AffaMed Therapeutics announced license agreement and collaboration for DEXTENZA® and OTX-TIC in Asia.
What are the Factors Driving Revenue Generation in the U.K.?
The U.K. market will account for over 24% of the Europe market through the assessment period ending in 2031. Common clinical developments, the demand for extensive product portfolios, and improvements in drug development pipelines and production capacities are key factors speeding growth in the U.K. market.
Some of the market players are focusing on acquisition to expand their portfolio for over-the-counter drugs in the U.K. market.
What are the Key Factors Enabling Growth in Germany?
Germany market will exhibit a 4.6% CAGR throughout the forecast period. Regulatory guidelines are relatively strict in Germany. As a result, achieving drug approvals is hard process. Germany is the second leading market in Europe. Some of the leading players are eying to expand their footprint in Germany.
For instance, Vision Ophthalmology Group GmbH is acquired by AddLife AB, an independent operator in Life Science that offers high-quality products and services within a wide variety of therapeutic areas to both private and public sectors across Europe.
What are the Favorable Policies Driving Japan Market?
The Japan market will account for more than 52% of the sales registered in East Asia in 2021. Increasing healthcare spending has improved the quality of healthcare, while boosting the demand for pharmaceutical products in Japan.
According to International Trade Administration, the overall Japan market for prescription as well as over-the-counter drugs totalled US$ 105 Bn in 2019. The government of Japan provides for healthcare spending of around 40% people living in the country via the national insurance schemes. These policies will continue favoring expansion of the market in Japan.
Japan’s pharmaceutical sector will showcase a moderate growth in the comig years due to high pricing. Despite this, it will remain a favourable destination for international biopharmaceutical companies for drug development and innovative therapies.
Ocular Drug Delivery System Market - Category-wise Insights
What is Nano-Particle Drug Delivery Systems Revenue by Technology?
Nano-Particle drug delivery systems has a higher potential for growth in the coming years. It is likely to exhibit a CAGR of 7.6% in the near future. Nanoparticles have been designed to overcome the barriers, increasing the drug penetration at the target site and prolonging the drug levels by few internals of drug administrations in lower doses without any toxicity compared to the conventional eye drops.
What is the Market Share of Ophthalmic Solution?
Ophthalmic solution will continue to dominate the market during the forecast period and it is expected to hold around 60% of the market share through the end of 2031.
What is the Scope for Growth of Mail Order Pharmacies?
While hospital pharmacies are currently leading the market, mail order pharmacies will exhibit high growth in the ocular drug delivery systems market at 8.9% CAGR in the forecast period. This will be primarily due to higher acceptance of online sales channel that provide discounts and offers, which reduces the overall costs of systems and medications.
Ocular Drug Delivery System Market - Competitive Landscape
Manufacturers in the ocular drug delivery system market are primarily aiming to carry out strategic collaborations and R&D to consolidate growth in a competitive and fragmented market.
For Instance, on March 31, 2017, Clear side Biomedical entered into a strategic collaboration with EyeKor to support Clearside’s clinical development efforts.
In September, 2020, Bausch Health Companies Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Alaway® Preservative Free (ketotifen fumarate) ophthalmic solution, 0.035%, antihistamine eye drops (EM-100)
In January 2020, In February, 2021, Alimera Sciences continued Global geographic expansion with launch of ILUVIEN in Finland.
Ocular Drug Delivery System Market - Scope of the Report
|
Attribute |
Details |
|
Ocular Drug Delivery System Market - Forecast Period |
2021-2031 |
|
Historical Data Available for |
2016-2020 |
|
Ocular Drug Delivery System Market - Analysis |
USD Million for Value/ Units in Million for Volume |
|
Ocular Drug Delivery System Market - Key Countries Covered |
US, Canada, Germany, U.K., France, Italy, Spain, Poland, Russia, China, Japan, South Korea, India, Thailand, Malaysia, Indonesia, Australia, New Zealand, GCC Countries, Turkey, South Africa |
|
Ocular Drug Delivery System Market - Key Segments Covered |
Technology, Dosage Form, Distribution Channel, and Region |
|
Ocular Drug Delivery System Market - Key Companies Profiled |
|
|
Report Coverage |
Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
|
Customization & Pricing |
Available upon Request |
Ocular Drug Delivery Systems Market by Category
Technology:
- Implantable Ocular Drug Delivery Systems
- Particulate Drug Delivery Systems
- Nano-Particle Drug Delivery System
Dosage Form:
- Ophthalmic Solution
- Ophthalmic Suspension
- Ophthalmic Emulsion
- Ophthalmic Gels
- Ophthalmic Ointments
Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Drug Store
- Mail Order Pharmacies
Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East and Africa (MEA)
Frequently Asked Questions
The ocular drug delivery systems market is forecast to surpass a valuation of US$ 27.82 Bn by 2031.
According to FMI’s analysis, the demand for ocular drug delivery systems consistently rose, at a CAGR of 5.1% between 2016 and 2020.
It is a prevalent trend among the market players to focus on development and modification of drug properties. Through this, they intend to improve drug permeation and drug bioavailability.
The ocular drug delivery systems market will continue gaining from the increasing adoption of patient compliant nanomedicine based therapeutic agents that offer improved efficacy for the treatment of anterior and posterior segment ocular disorders.
North America will remain dominant in the global market. At presents it holds around 51% of the overall ocular drug delivery systems market. Canada will emerge as the fastest growth market within North America, yet the U.S. is forecast to remain dominant through the assessment period.
The U.S., Canada, U.K., Germany, and Japan are the key markets of ocular drug delivery systems.
The top five players in ocular drug delivery systems market are Valeant Pharmaceuticals International, Inc, Santen Pharmaceutical Co., Ltd, Allergan, Plc, Alimera Sciences, and Vision Ophthalmology Group GmbH. These companies account for nearly 68% of the global market share.
As per FMI analysis, the Europe ocular drug delivery systems market is expected to rise at a CAGR of 6.6% between 2021 and 2031.
The Japan ocular drug delivery systems market is expected to exhibit growth at 6.1% CAGR during the forecast period. South Korea holds a revenue share of 0.4% in the global ocular drug delivery systems market.
Table of Content
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusion & Exclusion
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends
4. Market Background
4.1. Macro-Economic Factors
4.1.1. GDP Growth Outlook
4.1.2. Global Healthcare Industry Outlook
4.1.3. Increasing Per Capita Healthcare Spending
4.1.4. Income Per Capita Outlook
4.2. Forecast Factors - Relevance & Impact
4.2.1. Product Availability
4.2.2. Rising Demand of Non-Invasive Ocular Drug Delivery Techniques
4.2.3. Global Ocular Drug Delivery Systems Market Statistics
4.2.4. Increase in Technological Advancement
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunity Analysis
5. Market Context
5.1. Key Product Features and Their USPs
5.2. Product Adoption / Usage Analysis
5.3. Key Promotional Strategies, By Manufacturers
5.4. Regulations, By Region
5.5. Reimbursement Scenario
6. COVID19 Crisis Analysis
6.1. Current Economic Projection as compared to 2008 financial analysis
6.2. COVID19 and Impact Analysis
6.2.1. Revenue by Product
6.2.2. Revenue by Dosage Form
6.2.3. Revenue by Distribution Channel
6.2.4. Revenue by Country
6.3. 2020 Market Scenario
7. Global Ocular Drug Delivery Systems Market Volume (Units) Analysis 2016-2020 and Forecast, 2021-2031
7.1. Historical Market Volume (Units) Analysis, 2016-2020
7.2. Current and Future Market Volume (Units) Projections, 2021-2031
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Ocular Drug Delivery Systems Market - Pricing Analysis
8.1. Country Pricing Analysis by Technology
8.2. Pricing Break-up
8.2.1. Manufacturer Level Pricing
8.2.2. Distributor Level Pricing
8.3. Latin America and Middle East Average Pricing Analysis Benchmark
9. Global Ocular Drug Delivery Systems Market Value Analysis 2016-2020 and Forecast, 2021-2031
9.1. Historical Market Value (US$ Mn) Analysis, 2016-2020
9.2. Current and Future Market Value (US$ Mn) Projections, 2021-2031
9.2.1. Y-o-Y Growth Trend Analysis
9.2.2. Absolute $ Opportunity Analysis
10. Global Ocular Drug Delivery Systems Market Analysis 2016-2020 and Forecast 2021-2031, by Technology
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Mn) Analysis by Technology, 2016-2020
10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Technology, 2021-2031
10.3.1. Implantable Ocular Drug Delivery Systems
10.3.2. Particulate Drug Delivery Systems
10.3.3. Nano-Particle drug Delivery systems
10.4. Market Attractiveness Analysis by Technology
11. Global Ocular Drug Delivery Systems Market Analysis 2016-2020 and Forecast 2021-2031, by Dosage Form
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Mn) Analysis by Dosage Form, 2016-2020
11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Dosage Form, 2021-2031
11.3.1. Ophthalmic Solution
11.3.2. Ophthalmic Suspension
11.3.3. Ophthalmic Emulsion
11.3.4. Ophthalmic Gels
11.3.5. Ophthalmic Ointments
11.4. Market Attractiveness Analysis by Dosage Form
12. Global Ocular Drug Delivery Systems Market Analysis 2016-2020 and Forecast 2021-2031, By Distribution Channel
12.1. Introduction / Key Findings
12.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2016-2020
12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2021-2031
12.3.1. Hospital Pharmacies
12.3.2. Retail Pharmacies
12.3.3. Drug Stores
12.3.4. Mail Order Pharmacies
12.4. Market Attractiveness Analysis by Distribution Channel
13. Global Ocular Drug Delivery Systems Market Analysis 2016-2020 and Forecast 2021-2031, by Region
13.1. Introduction
13.2. Historical Market Size (US$ Mn) Analysis By Region, 2016-2020
13.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2021-2031
13.3.1. North America
13.3.2. Latin America
13.3.3. Europe
13.3.4. East Asia
13.3.5. South Asia
13.3.6. Oceania
13.3.7. Middle East and Africa (MEA)
13.4. Market Attractiveness Analysis By Region
14. North America Ocular Drug Delivery Systems Market Analysis 2016-2020 and Forecast 2021-2031
14.1. Introduction
14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2020
14.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2021-2031
14.3.1. By Country
14.3.1.1. U.S.
14.3.1.2. Canada
14.3.2. By Technology
14.3.3. By Dosage Form
14.3.4. By Distribution Channel
14.4. Market Attractiveness Analysis
14.5. Key Market Participants - Intensity Mapping
14.6. Drivers and Restraints - Impact Analysis
15. Latin America Ocular Drug Delivery Systems Market Analysis 2016-2020 and Forecast 2021-2031
15.1. Introduction
15.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2020
15.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2021-2031
15.3.1. By Country
15.3.1.1. Brazil
15.3.1.2. Mexico
15.3.1.3. Argentina
15.3.1.4. Rest of Latin America
15.3.2. By Technology
15.3.3. By Dosage Form
15.3.4. By Distribution Channel
15.4. Market Attractiveness Analysis
15.5. Key Market Participants - Intensity Mapping
15.6. Drivers and Restraints - Impact Analysis
16. Europe Ocular Drug Delivery Systems Market Analysis 2016-2020 and Forecast 2021-2031
16.1. Introduction
16.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2020
16.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2021-2031
16.3.1. By Country
16.3.1.1. Germany
16.3.1.2. Italy
16.3.1.3. France
16.3.1.4. U.K.
16.3.1.5. Spain
16.3.1.6. Russia
16.3.1.7. Rest of Europe
16.3.2. By Technology
16.3.3. By Dosage Form
16.3.4. By Distribution Channel
16.4. Market Attractiveness Analysis
16.5. Key Market Participants - Intensity Mapping
16.6. Drivers and Restraints - Impact Analysis
17. South Asia Ocular Drug Delivery Systems Market Analysis 2016-2020 and Forecast 2021-2031
17.1. Introduction
17.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2020
17.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2021-2031
17.3.1. By Country
17.3.1.1. India
17.3.1.2. Thailand
17.3.1.3. Indonesia
17.3.1.4. Malaysia
17.3.1.5. Rest of South Asia
17.3.2. By Technology
17.3.3. By Dosage Form
17.3.4. By Distribution Channel
17.4. Market Attractiveness Analysis
17.5. Key Market Participants - Intensity Mapping
17.6. Drivers and Restraints - Impact Analysis
18. East Asia Ocular Drug Delivery Systems Market Analysis 2016-2020 and Forecast 2021-2031
18.1. Introduction
18.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2020
18.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2021-2031
18.3.1. By Country
18.3.1.1. China
18.3.1.2. Japan
18.3.1.3. South Korea
18.3.1.4. Rest of East Asia
18.3.2. By Technology
18.3.3. By Dosage Form
18.3.4. By Distribution Channel
18.4. Market Attractiveness Analysis
18.5. Key Market Participants - Intensity Mapping
18.6. Drivers and Restraints - Impact Analysis
19. Oceania Ocular Drug Delivery Systems Market Analysis 2016-2020 and Forecast 2021-2031
19.1. Introduction
19.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2020
19.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2021-2031
19.3.1. By Country
19.3.1.1. Australia
19.3.1.2. New Zealand
19.3.2. By Technology
19.3.3. By Dosage Form
19.3.4. By Distribution Channel
19.4. Market Attractiveness Analysis
19.5. Key Market Participants - Intensity Mapping
19.6. Drivers and Restraints - Impact Analysis
20. Middle East and Africa Ocular Drug Delivery Systems Market Analysis 2016-2020 and Forecast 2021-2031
20.1. Introduction
20.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2020
20.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2021-2031
20.3.1. By Country
20.3.1.1. GCC Countries
20.3.1.2. South Africa
20.3.1.3. Rest of Middle East and Africa
20.3.2. By Technology
20.3.3. By Dosage Form
20.3.4. By Distribution Channel
20.4. Market Attractiveness Analysis
20.5. Key Market Participants - Intensity Mapping
20.6. Drivers and Restraints - Impact Analysis
21. Key and Emerging Countries Ocular Drug Delivery Systems Market Analysis 2016-2020 and Forecast 2021-2031
21.1. Introduction
21.1.1. Market Value Proportion Analysis, By Key Countries
21.1.2. Global Vs. Country Growth Comparison
21.2. U.S. Ocular Drug Delivery Systems Market Analysis
21.2.1. By Technology
21.2.2. By Dosage Form
21.2.3. By Distribution Channel
21.3. Canada Ocular Drug Delivery Systems Market Analysis
21.3.1. By Technology
21.3.2. By Dosage Form
21.3.3. By Distribution Channel
21.4. Mexico Ocular Drug Delivery Systems Market Analysis
21.4.1. By Technology
21.4.2. By Dosage Form
21.4.3. By Distribution Channel
21.5. Brazil Ocular Drug Delivery Systems Market Analysis
21.5.1. By Technology
21.5.2. By Dosage Form
21.5.3. By Distribution Channel
21.6. U.K. Ocular Drug Delivery Systems Market Analysis
21.6.1. By Technology
21.6.2. By Dosage Form
21.6.3. By Distribution Channel
21.7. Germany Ocular Drug Delivery Systems Market Analysis
21.7.1. By Technology
21.7.2. By Dosage Form
21.7.3. By Distribution Channel
21.8. France Ocular Drug Delivery Systems Market Analysis
21.8.1. By Technology
21.8.2. By Dosage Form
21.8.3. By Distribution Channel
21.9. Italy Ocular Drug Delivery Systems Market Analysis
21.9.1. By Technology
21.9.2. By Dosage Form
21.9.3. By Distribution Channel
21.10. Spain Ocular Drug Delivery Systems Market Analysis
21.10.1. By Technology
21.10.2. By Dosage Form
21.10.3. By Distribution Channel
21.11. BENELUX Ocular Drug Delivery Systems Market Analysis
21.11.1. By Technology
21.11.2. By Dosage Form
21.11.3. By Distribution Channel
21.12. Russia Ocular Drug Delivery Systems Market Analysis
21.12.1. By Technology
21.12.2. By Dosage Form
21.12.3. By Distribution Channel
21.13. China Ocular Drug Delivery Systems Market Analysis
21.13.1. By Technology
21.13.2. By Dosage Form
21.13.3. By Distribution Channel
21.14. Japan Ocular Drug Delivery Systems Market Analysis
21.14.1. By Technology
21.14.2. By Dosage Form
21.14.3. By Distribution Channel
21.15. South Korea Ocular Drug Delivery Systems Market Analysis
21.15.1. By Technology
21.15.2. By Dosage Form
21.15.3. By Distribution Channel
21.16. India Ocular Drug Delivery Systems Market Analysis
21.16.1. By Technology
21.16.2. By Dosage Form
21.16.3. By Distribution Channel
21.17. ASEAN Ocular Drug Delivery Systems Market Analysis
21.17.1. By Technology
21.17.2. By Dosage Form
21.17.3. By Distribution Channel
21.18. Australia Ocular Drug Delivery Systems Market Analysis
21.18.1. By Technology
21.18.2. By Dosage Form
21.18.3. By Distribution Channel
21.19. New Zealand Ocular Drug Delivery Systems Market Analysis
21.19.1. By Technology
21.19.2. By Dosage Form
21.19.3. By Distribution Channel
21.20. GCC Countries Ocular Drug Delivery Systems Market Analysis
21.20.1. By Technology
21.20.2. By Dosage Form
21.20.3. By Distribution Channel
21.21. Turkey Ocular Drug Delivery Systems Market Analysis
21.21.1. By Technology
21.21.2. By Dosage Form
21.21.3. By Distribution Channel
21.22. South Africa Ocular Drug Delivery Systems Market Analysis
21.22.1. By Technology
21.22.2. By Dosage Form
21.22.3. By Distribution Channel
22. Market Structure Analysis
22.1. Market Analysis by Tier of Companies
22.2. Market Concentration
22.3. Market Share Analysis of Top Players
22.4. Market Presence Analysis
22.4.1. By Regional Foot Print of Players
22.4.2. Product Foot Print by Players
22.4.3. Channel Foot Print by Players
23. Competition Analysis
23.1. Competition Dashboard
23.2. Competition Benchmarking
23.3. Competition Deep Dive
23.3.1. Allergan Plc.
23.3.1.1. Overview
23.3.1.2. Product Portfolio
23.3.1.3. Analyst Commentary
23.3.1.4. Key Financials
23.3.1.5. Recent Developments
23.3.1.6. Sales Footprint
23.3.1.7. Strategy Overview
23.3.1.7.1. Marketing Strategy
23.3.1.7.2. Product Strategy
23.3.1.7.3. Channel Strategy
23.3.2. Graybug Vision Inc.
23.3.2.1. Overview
23.3.2.2. Product Portfolio
23.3.2.3. Analyst Commentary
23.3.2.4. Key Financials
23.3.2.5. Recent Developments
23.3.2.6. Sales Footprint
23.3.2.7. Strategy Overview
23.3.2.7.1. Marketing Strategy
23.3.2.7.2. Product Strategy
23.3.2.7.3. Channel Strategy
23.3.3. Ocular Therapeutix, Inc.
23.3.3.1. Overview
23.3.3.2. Product Portfolio
23.3.3.3. Analyst Commentary
23.3.3.4. Key Financials
23.3.3.5. Recent Developments
23.3.3.6. Sales Footprint
23.3.3.7. Strategy Overview
23.3.3.7.1. Marketing Strategy
23.3.3.7.2. Product Strategy
23.3.3.7.3. Channel Strategy
23.3.4. Alimera Sciences
23.3.4.1. Overview
23.3.4.2. Product Portfolio
23.3.4.3. Analyst Commentary
23.3.4.4. Key Financials
23.3.4.5. Recent Developments
23.3.4.6. Sales Footprint
23.3.4.7. Strategy Overview
23.3.4.7.1. Marketing Strategy
23.3.4.7.2. Product Strategy
23.3.4.7.3. Channel Strategy
23.3.5. pSivida
23.3.5.1. Overview
23.3.5.2. Product Portfolio
23.3.5.3. Analyst Commentary
23.3.5.4. Key Financials
23.3.5.5. Recent Developments
23.3.5.6. Sales Footprint
23.3.5.7. Strategy Overview
23.3.5.7.1. Marketing Strategy
23.3.5.7.2. Product Strategy
23.3.5.7.3. Channel Strategy
23.3.6. Santen Pharmaceutical Co., Ltd
23.3.6.1. Overview
23.3.6.2. Product Portfolio
23.3.6.3. Analyst Commentary
23.3.6.4. Key Financials
23.3.6.5. Recent Developments
23.3.6.6. Sales Footprint
23.3.6.7. Strategy Overview
23.3.6.7.1. Marketing Strategy
23.3.6.7.2. Product Strategy
23.3.6.7.3. Channel Strategy
23.3.7. Taiwan Liposome Company Ltd.
23.3.7.1. Overview
23.3.7.2. Product Portfolio
23.3.7.3. Analyst Commentary
23.3.7.4. Key Financials
23.3.7.5. Recent Developments
23.3.7.6. Sales Footprint
23.3.7.7. Strategy Overview
23.3.7.7.1. Marketing Strategy
23.3.7.7.2. Product Strategy
23.3.7.7.3. Channel Strategy
23.3.8. Envisia Therapeutics
23.3.8.1. Overview
23.3.8.2. Product Portfolio
23.3.8.3. Analyst Commentary
23.3.8.4. Key Financials
23.3.8.5. Recent Developments
23.3.8.6. Sales Footprint
23.3.8.7. Strategy Overview
23.3.8.7.1. Marketing Strategy
23.3.8.7.2. Product Strategy
23.3.8.7.3. Channel Strategy
23.3.9. Eyegate Pharma
23.3.9.1. Overview
23.3.9.2. Product Portfolio
23.3.9.3. Analyst Commentary
23.3.9.4. Key Financials
23.3.9.5. Recent Developments
23.3.9.6. Sales Footprint
23.3.9.7. Strategy Overview
23.3.9.7.1. Marketing Strategy
23.3.9.7.2. Product Strategy
23.3.9.7.3. Channel Strategy
23.3.10. Valeant Pharmaceuticals International, Inc
23.3.10.1. Overview
23.3.10.2. Product Portfolio
23.3.10.3. Analyst Commentary
23.3.10.4. Key Financials
23.3.10.5. Recent Developments
23.3.10.6. Sales Footprint
23.3.10.7. Strategy Overview
23.3.10.7.1. Marketing Strategy
23.3.10.7.2. Product Strategy
23.3.10.7.3. Channel Strategy
23.3.11. Vision Ophthalmology Group GmbH
23.3.11.1. Overview
23.3.11.2. Product Portfolio
23.3.11.3. Analyst Commentary
23.3.11.4. Key Financials
23.3.11.5. Recent Developments
23.3.11.6. Sales Footprint
23.3.11.7. Strategy Overview
23.3.11.7.1. Marketing Strategy
23.3.11.7.2. Product Strategy
23.3.11.7.3. Channel Strategy
23.3.12. Clearside Biomedical
23.3.12.1. Overview
23.3.12.2. Product Portfolio
23.3.12.3. Analyst Commentary
23.3.12.4. Key Financials
23.3.12.5. Recent Developments
23.3.12.6. Sales Footprint
23.3.12.7. Strategy Overview
23.3.12.7.1. Marketing Strategy
23.3.12.7.2. Product Strategy
23.3.12.7.3. Channel Strategy
23.3.13. URSAPHARM Arzneimittel GmbH
23.3.13.1. Overview
23.3.13.2. Product Portfolio
23.3.13.3. Analyst Commentary
23.3.13.4. Key Financials
23.3.13.5. Recent Developments
23.3.13.6. Sales Footprint
23.3.13.7. Strategy Overview
23.3.13.7.1. Marketing Strategy
23.3.13.7.2. Product Strategy
23.3.13.7.3. Channel Strategy
24. Assumptions and Acronyms Used
25. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 1: Global Ocular Drug Delivery Systems Market Volume (Mn Units) Analysis 2016-2020 and Forecast 2021-2031, By Dosage Form
Table 2: Global Ocular Drug Delivery Systems Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Technology Type
Table 3: Global Ocular Drug Delivery Systems Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Dosage Form
Table 4: Global Ocular Drug Delivery Systems Market Volume (Mn Units) Analysis 2016-2020 and Forecast 2021-2031, By Dosage Form
Table 5: Global Ocular Drug Delivery Systems Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Distribution Channel
Table 6: Global Ocular Drug Delivery Systems Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Region
Table 7: North America Ocular Drug Delivery Systems Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Country
Table 8: North America Ocular Drug Delivery Systems Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Technology Type
Table 9: North America Ocular Drug Delivery Systems Market Volume Units) Analysis 2016-2020 and Forecast 2021-2031, By Dosage Form
Table 10: North America Ocular Drug Delivery Systems Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Dosage Form
Table 11: North America Ocular Drug Delivery Systems Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Distribution Channel
Table 12: Latin America Ocular Drug Delivery Systems Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Country
Table 13: Latin America Ocular Drug Delivery Systems Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Technology Type
Table 14: Latin America Ocular Drug Delivery Systems Market Volume Units) Analysis 2016-2020 and Forecast 2021-2031, By Dosage Form
Table 15: Latin America Ocular Drug Delivery Systems Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Dosage Form
Table 16: Latin America Ocular Drug Delivery Systems Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Distribution Channel
Table 17: Europe Ocular Drug Delivery Systems Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Country
Table 18: Europe Ocular Drug Delivery Systems Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Technology Type
Table 19: Europe Ocular Drug Delivery Systems Market Volume Units) Analysis 2016-2020 and Forecast 2021-2031, By Dosage Form
Table 20: Europe Ocular Drug Delivery Systems Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Dosage Form
Table 21: Europe Ocular Drug Delivery Systems Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Distribution Channel
Table 22: South Asia Ocular Drug Delivery Systems Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Country
Table 23: South Asia Ocular Drug Delivery Systems Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Technology Type
Table 24: South Asia Ocular Drug Delivery Systems Market Volume Units) Analysis 2016-2020 and Forecast 2021-2031, By Dosage Form
Table 25: South Asia Ocular Drug Delivery Systems Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Dosage Form
Table 26: South Asia Ocular Drug Delivery Systems Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Distribution Channel
Table 27: East Asia Ocular Drug Delivery Systems Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Country
Table 28: East Asia Ocular Drug Delivery Systems Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Technology Type
Table 29: East Asia Ocular Drug Delivery Systems Market Volume Units) Analysis 2016-2020 and Forecast 2021-2031, By Dosage Form
Table 30: East Asia Ocular Drug Delivery Systems Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Dosage Form
Table 31: East Asia Ocular Drug Delivery Systems Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Distribution Channel
Table 32: Oceania Ocular Drug Delivery Systems Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Country
Table 33: Oceania Ocular Drug Delivery Systems Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Technology Type
Table 34: Oceania Ocular Drug Delivery Systems Market Volume Units) Analysis 2016-2020 and Forecast 2021-2031, By Dosage Form
Table 35: Oceania Ocular Drug Delivery Systems Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Dosage Form
Table 36: Oceania Ocular Drug Delivery Systems Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Distribution Channel
Table 37: MEA Ocular Drug Delivery Systems Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Country
Table 38: MEA Ocular Drug Delivery Systems Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Technology Type
Table 39: MEA Ocular Drug Delivery Systems Market Volume Units) Analysis 2016-2020 and Forecast 2021-2031, By Dosage Form
Table 40: MEA Ocular Drug Delivery Systems Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Dosage Form
Table 41: MEA Ocular Drug Delivery Systems Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Distribution Channel
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 1: Global Ocular Drug Delivery Systems Market Volume Y-o-Y Growth (%), By Dosage Form, 2020–2031
Figure 2: Global Ophthalmic Solution, Price Difference (US$) Per ml, By Region, 2020A
Figure 3: Global Ophthalmic Solution, Price Difference (US$) Per ml, By Region, 2031F
Figure 4: Global Ophthalmic Suspension, Price Difference (US$) Per ml, By Region, 2020A
Figure 5: Global Ophthalmic Suspension, Price Difference (US$) Per ml, By Region, 2031F
Figure 6: Global Ophthalmic Emulsion, Price Difference (US$) Per ml, By Region, 2020A
Figure 7: Global Ophthalmic Emulsion, Price Difference (US$) Per ml, By Region, 2031F
Figure 8: Global Ophthalmic Gels, Price Difference (US$) Per ml By Region, 2020A
Figure 9: Global Ophthalmic Gels, Price Difference (US$) Per ml, By Region, 2031F
Figure 10: Global Ophthalmic Ointments, Price Difference (US$) Per ml, By Region, 2020A
Figure 11: Global Ophthalmic Ointments, Price Difference (US$) Per ml, By Region, 2031F
Figure 12: Global Ocular Drug Delivery Systems Market Value Analysis (US$ Mn), 2016-2020
Figure 13: Global Ocular Drug Delivery Systems Market Value Analysis (US$ Mn), 2021-2031
Figure 14: Global Ocular Drug Delivery Systems Market Absolute $ Opportunity, 2016-2020
Figure 15: Global Ocular Drug Delivery Systems Market Absolute $ Opportunity, 2021-2031
Figure 16: Global Ocular Drug Delivery Systems Market Share Analysis (%) By Technology Type, 2021 & 2031
Figure 17: Global Ocular Drug Delivery Systems Market Y-o-Y Growth (%) By Technology Type, 2021-2031
Figure 18: Global Ocular Drug Delivery Systems Market Attractiveness Analysis, By Technology Type
Figure 19: Global Ocular Drug Delivery Systems Market Share Analysis (%) By Dosage Form, 2021 & 2031
Figure 20: Global Ocular Drug Delivery Systems Market Y-o-Y Growth (%) By Dosage Form, 2021-2031
Figure 21: Global Ocular Drug Delivery Systems Market Attractiveness Analysis, By Dosage Form
Figure 22: Global Ocular Drug Delivery Systems Market Share Analysis (%) By Distribution Channel, 2021 & 2031
Figure 23: Global Ocular Drug Delivery Systems Market Y-o-Y Growth (%) By Distribution Channel, 2021-2031
Figure 24: Global Ocular Drug Delivery Systems Market Attractiveness Analysis, By Distribution Channel
Figure 25: Global Ocular Drug Delivery Systems Market Share Analysis (%) By Region, 2021 & 2031
Figure 26: Global Ocular Drug Delivery Systems Market Y-o-Y Growth (%) By Region, 2021-2031
Figure 27: Global Ocular Drug Delivery Systems Market Attractiveness Analysis, By Region
Figure 28: North America Ocular Drug Delivery Systems Market Value Share By Technology Type (2021 E)
Figure 29: North America Ocular Drug Delivery Systems Market Value Share By Dosage Form (2021 E)
Figure 30: North America Ocular Drug Delivery Systems Market Value Share By Distribution Channel (2021 E)
Figure 31: North America Ocular Drug Delivery Systems Market Value Share By Country (2021 E)
Figure 32: North America Ocular Drug Delivery Systems Market Value (US$ Mn) Analysis, 2016-2020
Figure 33: North America Ocular Drug Delivery Systems Market Value (US$ Mn) & Y-o-Y Growth (%), 2020-2031
Figure 34: North America Ocular Drug Delivery Systems Market Attractiveness Analysis, By Technology Type, 2021-2031
Figure 35: North America Ocular Drug Delivery Systems Market Attractiveness Analysis, By Dosage Form, 2021-2031
Figure 36: North America Ocular Drug Delivery Systems Market Attractiveness Analysis, By Distribution Channel, 2021-2031
Figure 37: North America Ocular Drug Delivery Systems Market Attractiveness Analysis, By Country, 2021-2031
Figure 38: Latin America Ocular Drug Delivery Systems Market Value Share By Technology Type (2021 E)
Figure 39: Latin America Ocular Drug Delivery Systems Market Value Share By Dosage Form (2021 E)
Figure 40: Latin America Ocular Drug Delivery Systems Market Value Share By Distribution Channel (2021 E)
Figure 41: Latin America Ocular Drug Delivery Systems Market Value Share By Country (2021 E)
Figure 42: Latin America Ocular Drug Delivery Systems Market Value (US$ Mn) Analysis, 2016-2020
Figure 43: Latin America Ocular Drug Delivery Systems Market Value (US$ Mn) & Y-o-Y Growth (%), 2020-2031
Figure 44: Latin America Ocular Drug Delivery Systems Market Attractiveness Analysis, By Technology Type, 2021-2031
Figure 45: Latin America Ocular Drug Delivery Systems Market Attractiveness Analysis, By Dosage Form, 2021-2031
Figure 46: Latin America Ocular Drug Delivery Systems Market Attractiveness Analysis, By Distribution Channel, 2021-2031
Figure 47: Latin America Ocular Drug Delivery Systems Market Attractiveness Analysis, By Country, 2021-2031
Figure 48: Europe Ocular Drug Delivery Systems Market Value Share By Technology Type (2021 E)
Figure 49: Europe Ocular Drug Delivery Systems Market Value Share By Dosage Form (2021 E)
Figure 50: Europe Ocular Drug Delivery Systems Market Value Share By Distribution Channel (2021 E)
Figure 51: Europe Ocular Drug Delivery Systems Market Value Share By Country (2021 E)
Figure 52: Europe Ocular Drug Delivery Systems Market Value (US$ Mn) Analysis, 2016-2020
Figure 53: Europe Ocular Drug Delivery Systems Market Value (US$ Mn) & Y-o-Y Growth (%), 2020-2031
Figure 54: Europe Ocular Drug Delivery Systems Market Attractiveness Analysis, By Technology Type, 2021-2031
Figure 55: Europe Ocular Drug Delivery Systems Market Attractiveness Analysis, By Dosage Form , 2021-2031
Figure 56: Europe Ocular Drug Delivery Systems Market Attractiveness Analysis, By Distribution Channel, 2021-2031
Figure 57: Europe Ocular Drug Delivery Systems Market Attractiveness Analysis, By Country, 2021-2031
Figure 58: South Asia Ocular Drug Delivery Systems Market Value Share By Technology Type (2021 E)
Figure 59: South Asia Ocular Drug Delivery Systems Market Value Share By Dosage Form (2021 E)
Figure 60: South Asia Ocular Drug Delivery Systems Market Value Share By Distribution Channel (2021 E)
Figure 61: South Asia Ocular Drug Delivery Systems Market Value Share By Country (2021 E)
Figure 62: South Asia Ocular Drug Delivery Systems Market Value (US$ Mn) Analysis, 2016-2020
Figure 63: South Asia Ocular Drug Delivery Systems Market Value (US$ Mn) & Y-o-Y Growth (%), 2020-2031
Figure 64: South Asia Ocular Drug Delivery Systems Market Attractiveness Analysis, By Technology Type, 2021-2031
Figure 65: South Asia Ocular Drug Delivery Systems Market Attractiveness Analysis, By Dosage Form , 2021-2031
Figure 66: South Asia Ocular Drug Delivery Systems Market Attractiveness Analysis, By Distribution Channel, 2021-2031
Figure 67: South Asia Ocular Drug Delivery Systems Market Attractiveness Analysis, By Country, 2021-2031
Figure 68: East Asia Ocular Drug Delivery Systems Market Value Share By Technology Type (2021 E)
Figure 69: East Asia Ocular Drug Delivery Systems Market Value Share By Dosage Form (2021 E)
Figure 70: East Asia Ocular Drug Delivery Systems Market Value Share By Distribution Channel (2021 E)
Figure 71: East Asia Ocular Drug Delivery Systems Market Value Share By Country (2021 E)
Figure 72: East Asia Ocular Drug Delivery Systems Market Value (US$ Mn) Analysis, 2016-2020
Figure 73: East Asia Ocular Drug Delivery Systems Market Value (US$ Mn) & Y-o-Y Growth (%), 2020-2031
Figure 74: East Asia Ocular Drug Delivery Systems Market Attractiveness Analysis, By Technology Type, 2021-2031
Figure 75: East Asia Ocular Drug Delivery Systems Market Attractiveness Analysis, By Dosage Form, 2021-2031
Figure 76: East Asia Ocular Drug Delivery Systems Market Attractiveness Analysis, By Distribution Channel, 2021-2031
Figure 77: East Asia Ocular Drug Delivery Systems Market Attractiveness Analysis, By Country, 2021-2031
Figure 78: Oceania Ocular Drug Delivery Systems Market Value Share By Technology Type (2021 E)
Figure 79: Oceania Ocular Drug Delivery Systems Market Value Share By Dosage Form (2021 E)
Figure 80: Oceania Ocular Drug Delivery Systems Market Value Share By Distribution Channel (2021 E)
Figure 81: Oceania Ocular Drug Delivery Systems Market Value Share By Country (2021 E)
Figure 82: Oceania Ocular Drug Delivery Systems Market Value (US$ Mn) Analysis, 2016-2020
Figure 83: Oceania Ocular Drug Delivery Systems Market Value (US$ Mn) & Y-o-Y Growth (%), 2020-2031
Figure 84: Oceania Ocular Drug Delivery Systems Market Attractiveness Analysis, By Technology Type, 2021-2031
Figure 85: Oceania Ocular Drug Delivery Systems Market Attractiveness Analysis, By Dosage Form, 2021-2031
Figure 86: Oceania Ocular Drug Delivery Systems Market Attractiveness Analysis, By Distribution Channel, 2021-2031
Figure 87: Oceania Ocular Drug Delivery Systems Market Attractiveness Analysis, By Country, 2021-2031
Figure 88: MEA Ocular Drug Delivery Systems Market Value Share By Technology Type (2021 E)
Figure 89: MEA Ocular Drug Delivery Systems Market Value Share By Dosage Form (2021 E)
Figure 90: MEA Ocular Drug Delivery Systems Market Value Share By Distribution Channel (2021 E)
Figure 91: MEA Ocular Drug Delivery Systems Market Value Share By Country (2021 E)
Figure 92: MEA Ocular Drug Delivery Systems Market Value (US$ Mn) Analysis, 2016-2020
Figure 93: MEA Ocular Drug Delivery Systems Market Value (US$ Mn) & Y-o-Y Growth (%), 2020-2031
Figure 94: MEA Ocular Drug Delivery Systems Market Attractiveness Analysis, By Technology Type, 2021-2031
Figure 95: MEA Ocular Drug Delivery Systems Market Attractiveness Analysis, By Dosage Form , 2021-2031
Figure 96: MEA Ocular Drug Delivery Systems Market Attractiveness Analysis, By Distribution Channel, 2021-2031
Figure 97: MEA Ocular Drug Delivery Systems Market Attractiveness Analysis, By Country, 2021-2031
Figure 98: U.S. Ocular Drug Delivery Systems Market Value Analysis (US$ Mn), 2021 & 2031
Figure 99: U.S. Ocular Drug Delivery Systems Market Value Share, By Technology Type, 2021 & 2031
Figure 100: U.S. Ocular Drug Delivery Systems Market Value Share, By Dosage Form, 2021 & 2031
Figure 101: U.S. Ocular Drug Delivery Systems Market Value Share, By Distribution Channel, 2021 & 2031
Figure 102: Global Vs. U.S. Growth Comparison
Figure 103: Canada Ocular Drug Delivery Systems Market Value Analysis (US$ Mn), 2021 & 2031
Figure 104: Canada Ocular Drug Delivery Systems Market Value Share, By Technology Type, 2021 & 2031
Figure 105: Canada Ocular Drug Delivery Systems Market Value Share, By Dosage Form, 2021 & 2031
Figure 106: Canada Ocular Drug Delivery Systems Market Value Share, By Distribution Channel, 2021 & 2031
Figure 107: Global Vs. Canada Growth Comparison
Figure 108: Mexico Ocular Drug Delivery Systems Market Value Analysis (US$ Mn), 2021 & 2031
Figure 109: Mexico Ocular Drug Delivery Systems Market Value Share, By Technology Type, 2021 & 2031
Figure 110: Mexico Ocular Drug Delivery Systems Market Value Share, By Dosage Form, 2021 & 2031
Figure 111: Mexico Ocular Drug Delivery Systems Market Value Share, By Distribution Channel, 2021 & 2031
Figure 112: Global Vs. Mexico Growth Comparison
Figure 113: Brazil Ocular Drug Delivery Systems Market Value Analysis (US$ Mn), 2021 & 2031
Figure 114: Brazil Ocular Drug Delivery Systems Market Value Share, By Technology Type, 2021 & 2031
Figure 115: Brazil Ocular Drug Delivery Systems Market Value Share, By Dosage Form, 2021 & 2031
Figure 116: Brazil Ocular Drug Delivery Systems Market Value Share, By Distribution Channel, 2021 & 2031
Figure 117: Global Vs. Brazil Growth Comparison
Figure 118: U.K. Ocular Drug Delivery Systems Market Value Analysis (US$ Mn), 2021 & 2031
Figure 119: U.K. Ocular Drug Delivery Systems Market Value Share, By Technology Type, 2021 & 2031
Figure 120: U.K. Ocular Drug Delivery Systems Market Value Share, By Dosage Form, 2021 & 2031
Figure 121: U.K. Ocular Drug Delivery Systems Market Value Share, By Distribution Channel, 2021 & 2031
Figure 122: Global Vs. U.K. Growth Comparison
Figure 123: Germany Ocular Drug Delivery Systems Market Value Analysis (US$ Mn), 2021 & 2031
Figure 124: Germany Ocular Drug Delivery Systems Market Value Share, By Technology Type, 2021 & 2031
Figure 125: Germany Ocular Drug Delivery Systems Market Value Share, By Dosage Form, 2021 & 2031
Figure 126: Germany Ocular Drug Delivery Systems Market Value Share, By Distribution Channel, 2021 & 2031
Figure 127: Global Vs. Germany Growth Comparison
Figure 128: France Ocular Drug Delivery Systems Market Value Analysis (US$ Mn), 2021 & 2031
Figure 129: France Ocular Drug Delivery Systems Market Value Share, By Technology Type, 2021 & 2031
Figure 130: France Ocular Drug Delivery Systems Market Value Share, By Dosage Form, 2021 & 2031
Figure 131: France Ocular Drug Delivery Systems Market Value Share, By Distribution Channel, 2021 & 2031
Figure 132: Global Vs. France Growth Comparison
Figure 133: Italy Ocular Drug Delivery Systems Market Value Analysis (US$ Mn), 2021 & 2031
Figure 134: Italy Ocular Drug Delivery Systems Market Value Share, By Technology Type, 2021 & 2031
Figure 135: Italy Ocular Drug Delivery Systems Market Value Share, By Dosage Form, 2021 & 2031
Figure 136: Italy Ocular Drug Delivery Systems Market Value Share, By Distribution Channel, 2021 & 2031
Figure 137: Global Vs. Italy Growth Comparison
Figure 138: Spain Ocular Drug Delivery Systems Market Value Analysis (US$ Mn), 2021 & 2031
Figure 139: Spain Ocular Drug Delivery Systems Market Value Share, By Technology Type, 2021 & 2031
Figure 140: Spain Ocular Drug Delivery Systems Market Value Share, By Dosage Form, 2021 & 2031
Figure 141: Spain Ocular Drug Delivery Systems Market Value Share, By Distribution Channel, 2021 & 2031
Figure 142: Global Vs. Spain Growth Comparison
Figure 143: BENELUX Ocular Drug Delivery Systems Market Value Analysis (US$ Mn), 2021 & 2031
Figure 144: BENELUX Ocular Drug Delivery Systems Market Value Share, By Technology Type, 2021 & 2031
Figure 145: BENELUX Ocular Drug Delivery Systems Market Value Share, By Dosage Form, 2021 & 2031
Figure 146: BENELUX Ocular Drug Delivery Systems Market Value Share, By Distribution Channel, 2021 & 2031
Figure 147: Global Vs. BENELUX Growth Comparison
Figure 148: Russia Ocular Drug Delivery Systems Market Value Analysis (US$ Mn), 2021 & 2031
Figure 149: Russia Ocular Drug Delivery Systems Market Value Share, By Technology Type, 2021 & 2031
Figure 150: Russia Ocular Drug Delivery Systems Market Value Share, By Dosage Form, 2021 & 2031
Figure 151: Russia Ocular Drug Delivery Systems Market Value Share, By Distribution Channel, 2021 & 2031
Figure 152: Global Vs. Russia Growth Comparison
Figure 153: China Ocular Drug Delivery Systems Market Value Analysis (US$ Mn), 2021 & 2031
Figure 154: China Ocular Drug Delivery Systems Market Value Share, By Technology Type, 2021 & 2031
Figure 155: China Ocular Drug Delivery Systems Market Value Share, By Dosage Form, 2021 & 2031
Figure 156: China Ocular Drug Delivery Systems Market Value Share, By Distribution Channel, 2021 & 2031
Figure 157: Global Vs. China Growth Comparison
Figure 158: Japan Ocular Drug Delivery Systems Market Value Analysis (US$ Mn), 2021 & 2031
Figure 159: Japan Ocular Drug Delivery Systems Market Value Share, By Technology Type, 2021 & 2031
Figure 160: Japan Ocular Drug Delivery Systems Market Value Share, By Dosage Form, 2021 & 2031
Figure 161: Japan Ocular Drug Delivery Systems Market Value Share, By Distribution Channel, 2021 & 2031
Figure 162: Global Vs. Japan Growth Comparison
Figure 163: South Korea Ocular Drug Delivery Systems Market Value Analysis (US$ Mn), 2021 & 2031
Figure 164: South Korea Ocular Drug Delivery Systems Market Value Share, By Technology Type, 2021 & 2031
Figure 165: South Korea Ocular Drug Delivery Systems Market Value Share, By Dosage Form, 2021 & 2031
Figure 166: South Korea Ocular Drug Delivery Systems Market Value Share, By Distribution Channel, 2021 & 2031
Figure 167: Global Vs. South Korea Growth Comparison
Figure 168: India Ocular Drug Delivery Systems Market Value Analysis (US$ Mn), 2021 & 2031
Figure 169: India Ocular Drug Delivery Systems Market Value Share, By Technology Type, 2021 & 2031
Figure 170: India Ocular Drug Delivery Systems Market Value Share, By Dosage Form, 2021 & 2031
Figure 171: India Ocular Drug Delivery Systems Market Value Share, By Distribution Channel, 2021 & 2031
Figure 172: Global Vs. India Growth Comparison
Figure 173: Malaysia Ocular Drug Delivery Systems Market Value Analysis (US$ Mn), 2021 & 2031
Figure 174: Malaysia Ocular Drug Delivery Systems Market Value Share, By Technology Type, 2021 & 2031
Figure 175: Malaysia Ocular Drug Delivery Systems Market Value Share, By Dosage Form, 2021 & 2031
Figure 176: Malaysia Ocular Drug Delivery Systems Market Value Share, By Distribution Channel, 2021 & 2031
Figure 177: Global Vs. Malaysia Growth Comparison
Figure 178: Thailand Ocular Drug Delivery Systems Market Value Analysis (US$ Mn), 2021 & 2031
Figure 179: Thailand Ocular Drug Delivery Systems Market Value Share, By Technology Type, 2021 & 2031
Figure 180: Thailand Ocular Drug Delivery Systems Market Value Share, By Dosage Form, 2021 & 2031
Figure 181: Thailand Ocular Drug Delivery Systems Market Value Share, By Distribution Channel, 2021 & 2031
Figure 182: Global Vs. Thailand Growth Comparison
Figure 183: Indonesia Ocular Drug Delivery Systems Market Value Analysis (US$ Mn), 2021 & 2031
Figure 184: Indonesia Ocular Drug Delivery Systems Market Value Share, By Technology Type, 2021 & 2031
Figure 185: Indonesia Ocular Drug Delivery Systems Market Value Share, By Dosage Form, 2021 & 2031
Figure 186: Indonesia Ocular Drug Delivery Systems Market Value Share, By Distribution Channel, 2021 & 2031
Figure 187: Global Vs. Indonesia Growth Comparison
Figure 188: Australia Ocular Drug Delivery Systems Market Value Analysis (US$ Mn), 2021 & 2031
Figure 189: Australia Ocular Drug Delivery Systems Market Value Share, By Technology Type, 2021 & 2031
Figure 190: Australia Ocular Drug Delivery Systems Market Value Share, By Dosage Form, 2021 & 2031
Figure 191: Australia Ocular Drug Delivery Systems Market Value Share, By Distribution Channel, 2021 & 2031
Figure 192: Global Vs. Australia Growth Comparison
Figure 193: New Zealand Ocular Drug Delivery Systems Market Value Analysis (US$ Mn), 2021 & 2031
Figure 194: New Zealand Ocular Drug Delivery Systems Market Value Share, By Technology Type, 2021 & 2031
Figure 195: New Zealand Ocular Drug Delivery Systems Market Value Share, By Dosage Form, 2021 & 2031
Figure 196: New Zealand Ocular Drug Delivery Systems Market Value Share, By Distribution Channel, 2021 & 2031
Figure 197: Global Vs. New Zealand Growth Comparison
Figure 198: Turkey Ocular Drug Delivery Systems Market Value Analysis (US$ Mn), 2021 & 2031
Figure 199: Turkey Ocular Drug Delivery Systems Market Value Share, By Technology Type, 2021 & 2031
Figure 200: Turkey Ocular Drug Delivery Systems Market Value Share, By Dosage Form, 2021 & 2031
Figure 201: Turkey Ocular Drug Delivery Systems Market Value Share, By Distribution Channel, 2021 & 2031
Figure 202: Global Vs. Turkey Growth Comparison
Figure 203: GCC Countries Ocular Drug Delivery Systems Market Value Analysis (US$ Mn), 2021 & 2031
Figure 204: GCC Countries Ocular Drug Delivery Systems Market Value Share, By Technology Type, 2021 & 2031
Figure 205: GCC Countries Ocular Drug Delivery Systems Market Value Share, By Dosage Form, 2021 & 2031
Figure 206: GCC Countries Ocular Drug Delivery Systems Market Value Share, By Distribution Channel, 2021 & 2031
Figure 207: Global Vs. GCC Countries Growth Comparison
Figure 208: South Africa Ocular Drug Delivery Systems Market Value Analysis (US$ Mn), 2021 & 2031
Figure 209: South Africa Ocular Drug Delivery Systems Market Value Share, By Technology Type, 2021 & 2031
Figure 210: South Africa Ocular Drug Delivery Systems Market Value Share, By Dosage Form, 2021 & 2031
Figure 211: South Africa Ocular Drug Delivery Systems Market Value Share, By Distribution Channel, 2021 & 2031
Figure 212: Global Vs. South Africa Growth Comparison
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
